[EN] NOVEL ALLOSTERIC INHIBITORS OF PROTEASOME AND METHODS OF USE THEREOF [FR] NOUVEAUX INHIBITEURS ALLOSTÉRIQUES DU PROTÉASOME ET MÉTHODES D'UTILISATION ASSOCIÉES
[EN] NOVEL ALLOSTERIC INHIBITORS OF PROTEASOME AND METHODS OF USE THEREOF [FR] NOUVEAUX INHIBITEURS ALLOSTÉRIQUES DU PROTÉASOME ET MÉTHODES D'UTILISATION ASSOCIÉES
The versatile role of norbornene in C–H functionalization processes: concise synthesis of tetracyclic fused pyrroles via a threefold domino reaction
作者:Kersten M. Gericke、David I. Chai、Mark Lautens
DOI:10.1016/j.tet.2008.01.146
日期:2008.6
The synthesis of novel tetracyclic fused pyrrolesfrom 1-(2-iodophenyl)-1H-pyrrole and various bromoalkyl-aryl alkynes via a palladium(0)-catalyzed and norbornene-mediated threefold domino reaction is reported. PdCl2 and tri-2-furylphosphine (TFP) in the presence of norbornene and Cs2CO3 in CH3CN at 90 °C gave a variety of tetracyclic fused pyrroles in usually high yields. In the described reaction
报道了通过钯(0)催化和降冰片烯介导的三重多米诺反应,由1-(2-碘苯基)-1 H-吡咯和各种溴代烷基-芳基炔烃合成新型四环稠合吡咯。在降冰片烯和Cs 2 CO 3在90°C的CH 3 CN中存在时,PdCl 2和三-2-呋喃基膦(TFP)可以通常以高收率得到各种四环稠合吡咯。在所描述的反应顺序中,三个碳-碳键中的两个是通过未活化的芳基C-H键的官能化形成的。
Allosteric inhibitors of proteasome and methods of use thereof
申请人:THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
公开号:US10167259B2
公开(公告)日:2019-01-01
The present invention relates generally to novel allosteric regulators of proteasome activity, methods for preparation and use, and pharmaceutical compositions thereof. Specifically piperidine-2-carboxylic acid derivatives containing 1-oxo-aroyl group and a lipophilic ester side chain are disclosed as allosteric inhibitors of proteasome 2S activity, and as therapeutic agents for the treatment of proteasome-associated disorders in a subject.
NOVEL ALLOSTERIC INHIBITORS OF PROTEASOME AND METHODS OF USE THEREOF
申请人:THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
公开号:US20160152567A1
公开(公告)日:2016-06-02
The present invention relates generally to novel allosteric regulators of proteasome activity, methods for preparation and use, and pharmaceutical compositions thereof. Specifically piperidine-2-carboxylic acid derivatives containing 1-oxo-aroyl group and a lipophilic ester side chain are disclosed as allosteric inhibitors of proteasome 2S activity, and as therapeutic agents for the treatment of proteasome-associated disorders in a subject.